PRO-1160

N/A

Report date: 2025/11/20 14:58:46

Base Information

Drug NamePRO-1160
Drug Alias NamePRO-1160GEN-1160GEN1160
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Exatecan payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-CD70
TargetsCD70 antigen
Therapy Area/IndicationsSolid tumoursNasopharyngeal CarcinomaCarcinoma, Renal Cell +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesProfoundBio (Suzhou) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesN/A
Inactive CompaniesProfoundBio (Suzhou) Co LtdGenmab A/S
Active IndicationsN/A
Inactive IndicationsSolid tumoursNasopharyngeal CarcinomaCarcinoma, Renal Cell +[5] 

Other Information

ATC CodeN/A
Related LinksN/A